ASH Experts Speak | Professor Lu Peihua: CD7 Universal CAR-T Therapy Brings Breakthrough Hope for Patients with R/R T-ALL/LBL
For patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL), current treatment options remain limited and outcomes are unsatisfactory, posing major clinical challenges. At the Annual Meeting of the…









